Analysis Clinical trials

Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise

Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.

VigiEye editorial · Thu 19 Nov 2026

What Lantern disclosed

On 18 November 2026, Lantern Pharma Inc. reported third-quarter results in an exhibit to a US filing. The release covered four things: clinical progress for its two oncology programs, LP-184 and LP-300; the opening of its first triple-negative breast cancer (TNBC) trial site; the start of HARMONIC Part 2 in Taiwan; and a roughly $4.0M offering. It also said the CEO has resigned.

The record we have is a summary of that release. It does not say which program the TNBC site belongs to or how many sites are planned. It also gives no enrollment figures and no efficacy or safety data. The summary does not cover the offering's terms or who will lead the company next, and we have not assumed either. Readers should check the primary filing for those details.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →